Glaxo Pops But Analysts Say It's Unlikely To Swipe Gilead Share In HIV
GlaxoSmithKline popped Thursday after its two-drug HIV treatment proved non-inferior to a three-drug regimen using medicine from Gilead Sciences. But analysts say Glaxo is unlikely to get much share from Gilead.